证券代码：600645 证券简称：中源协和 公告编号：2025-031 中源协和细胞基因工程股份有限公司 关于与上海延藜生物技术有限公司签署房地产租赁 合同暨关联交易的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●交易简要内容：基于公司战略规划需要，公司计划在上海设立华东总部。 经友好协商，公司拟与上海延藜生物技术有限公司（以下简称"上海延藜公司"） 签订房地产租赁合同，公司向上海延藜公司租赁其房地产作为华东总部办公使 用，具体房地产为上海延藜公司从上海春光实业有限公司承租的上海市普陀区泸 定路 276 弄 5 号楼（共 5 层）。其中 1 层部分区域提供公司无偿使用，作为公司 产品体验中心；2 层公司与上海延藜公司无偿共用，用作客户接待区域。第 3、4、 5 层承租作办公使用。优惠后的全部租金为人民币 12,239,910 元。 ●至本次关联交易为止，过去 12 个月与同一关联人以及与不同关联人进行 的交易类别相关的关联交易（日常关联交易除外）的累计次数为 2 次：协和干细 胞基因工程有限公司继续委 ...

中源协和细胞基因工程股份有限公司 十一届二十次临时董事会会议决议公告 证券代码：600645 证券简称：中源协和 公告编号：2025-029 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届二十次 临时董事会会议于 2025 年 7 月 28 日以通讯表决方式召开。会议通知和会议资 料已于 2025 年 7 月 23 日以电子邮件形式向全体董事发出。应出席会议的董事 9 名，实际出席会议的董事 9 名。会议符合《公司法》和《公司章程》的规 定，表决有效。经出席会议的董事认真审议，通过了以下决议： 1、以 7 票赞成、0 票反对、0 票弃权，审议通过了《关于收购子公司上海 中源济生细胞科技有限公司股东所持部分股权暨关联交易的议案》； 本议案经公司第十一届董事会独立董事专门会议 2025 年第二次会议审议通 过。 具体详见同日公告《公司关于与上海延藜生物技术有限公司签署房地产租 赁合同暨关联交易的公告》。 关联董事龚虹嘉先生、吴珊女士回避表决。 特此公告。 本议案经公司第十 ...

Core Viewpoint - The gene sequencing sector has shown a modest increase of 0.44%, ranking fifth among concept sectors, with notable performances from stocks like Nanjing Xinbai and Zhaoyan New Drug [1][2]. Market Performance - The gene sequencing concept saw 29 stocks rise, with Nanjing Xinbai hitting the daily limit up, and other top gainers including Heyuan Biological and Qianyuan Pharmaceutical, which rose by 8.61%, 6.96%, and 6.43% respectively [1]. - Conversely, stocks like Puni Testing, Zhongyuan Co., and Betta Pharmaceuticals experienced declines of 3.73%, 2.71%, and 2.46% respectively [1]. Capital Flow - The gene sequencing sector attracted a net inflow of 122 million yuan, with 34 stocks receiving net inflows, and 8 stocks exceeding 30 million yuan in net inflow [2]. - Zhaoyan New Drug led the sector with a net inflow of 203 million yuan, followed by Nanjing Xinbai and Qianyuan Pharmaceutical with net inflows of 111 million yuan and 64.63 million yuan respectively [2]. Capital Inflow Ratios - Nanjing Xinbai, Zhaoyan New Drug, and Heyuan Biological had the highest net inflow ratios at 43.57%, 12.72%, and 10.88% respectively [3].

Group 1 - The company held its 19th temporary board meeting on July 9, 2025, via telecommunication, with all 9 attending directors agreeing to waive the notice period due to urgency [1] - The board approved the appointment of Mr. Chen Yiqing as the secretary of the board, with a term lasting until the current board's term ends [1][2] - Mr. Chen Yiqing possesses the necessary qualifications and experience to fulfill the role of board secretary, having obtained the required training certification and meeting legal requirements [2] Group 2 - The company’s subsidiary, Beijing Zhongshan Jinqiao Biotechnology Co., Ltd., plans to donate a total of 3 million yuan, with 2 million yuan to the Peking Union Medical Foundation and 1 million yuan to the Beijing Red Cross Foundation, aimed at supporting public welfare projects [2] - This donation is part of the company's commitment to social responsibility and is expected to enhance its image and social influence [2] - The funds for the donation will come from the company's own resources and will not significantly impact its operational performance or harm the interests of shareholders, particularly minority shareholders [2]

证券代码：600645 证券简称：中源协和 公告编号：2025-028 中源协和细胞基因工程股份有限公司 十一届十九次临时董事会会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 中源协和细胞基因工程股份有限公司（以下简称"公司"）十一届十九次 临时董事会会议于 2025 年 7 月 9 日以通讯表决方式召开。会议通知和会议资料 已于 2025 年 7 月 8 日以电子邮件形式向全体董事发出。因情况紧急，召集人进 行了说明，全体董事一致同意豁免本次会议通知时限。应出席会议的董事 9 名，实际出席会议的董事 9 名。会议符合《公司法》和《公司章程》的规定， 表决有效。经出席会议的董事认真审议，通过了以下决议： 1、以 9 票赞成、0 票反对、0 票弃权，审议通过了《关于聘任董事会秘书 的议案》； 构成重大影响，不存在损害公司及全体股东特别是中小股东利益的情形。 特此公告。 中源协和细胞基因工程股份有限公司董事会 二○二五年七月十日 经董事长提名，董事会提名委员会审核通过，同意聘任陈轶青先生为公司 董事会秘书，聘期至本届 ...

Group 1 - The A-share market for monoclonal antibody concepts is active, with companies like Sai Sheng Pharmaceutical and Hainan Hai Pharmaceutical seeing gains of over 9% [1] - Other stocks such as Yiling Pharmaceutical, Zhongyuan Qihua, and Fudan Zhangjiang also experienced upward movement [1] - The collaboration between Hong Kong's cornerstone pharmaceutical company and European firm Gentili regarding Sugli monoclonal antibody is expected to boost the innovative drug market [1]

Market Overview - The market experienced slight fluctuations with an overall downward trend, as the indices showed mixed results with the Shanghai Composite Index up by 0.32% while the Shenzhen Component and ChiNext fell by 0.25% and 0.36% respectively [4] - Over 4,100 stocks declined while more than 1,100 stocks rose, indicating a bearish sentiment in the market [4] Sector Performance - The power sector showed significant strength, with stocks like Huayin Power and Huaguang Huaneng hitting the daily limit, and others like Dishen Co. reaching a 20% limit up [3][12] - The gaming sector also saw some gains, with stocks such as Giant Network hitting the limit up, while several others performed well [3] - The innovative drug sector experienced a resurgence, with stocks like Guangshengtang and Zhongyuan Qihua reaching the limit up, and others showing gains exceeding 10% [3] - Financial stocks rallied in the afternoon, with companies like Xiangcai Co. and Dazhihui hitting the limit up, although the gains were not sustained [6][7] Power Sector Insights - The power sector has been on a continuous rise, driven by extreme high temperatures leading to increased electricity demand, with the State Grid predicting a peak load of over 1.2 billion kilowatts this summer [14] - Huayin Power reported a significant profit increase in its mid-year earnings forecast, projecting a net profit of 180 million to 220 million yuan, marking a growth of 36.01 to 44.23 times compared to the previous year [14][15] Financial Sector Dynamics - The financial sector saw a brief surge in the afternoon, with major players like Tianfeng Securities and Dongfang Caifu experiencing collective gains, although these were followed by a retreat [6][8] - The market sentiment briefly shifted towards optimism, with discussions of a potential bull market, although this was short-lived [8] Birth Support Policy - A document regarding national-level birth subsidies was circulated, leading to a temporary uptick in stocks related to the dairy and baby products sectors [10][11] - The proposed subsidy is set at 3,600 yuan per year for children under three years old, translating to 300 yuan per month, although the impact on the market was limited and short-lived [11]

Group 1 - The recombinant protein concept sector increased by 0.80%, ranking 7th among concept sectors, with 16 stocks rising, including Hotgen Biotech and Zhongyuan Union, both hitting the daily limit [1][2] - The leading gainers in the recombinant protein sector included Huayu Pharmaceutical and Shenzhou Cell, which rose by 18.79% and 16.46% respectively [1][2] - The sector experienced a net inflow of 0.35 billion yuan, with 13 stocks receiving net inflows, and 9 stocks exceeding 10 million yuan in net inflow [2][3] Group 2 - Zhongyuan Union led the net inflow with 1.83 billion yuan, followed by Huayu Pharmaceutical and Hotgen Biotech with net inflows of 1.19 billion yuan and 796.26 million yuan respectively [2][3] - The top stocks by net inflow ratio included Zhongyuan Union at 20.01%, Huayu Pharmaceutical at 12.48%, and Tonghua Dongbao at 9.43% [3][4] - The overall performance of the recombinant protein sector was supported by significant capital inflows, indicating strong investor interest [2][3]

Group 1 - The innovative drug concept index rose by 0.72%, ranking 9th among concept sectors, with 108 stocks increasing in value [1][2] - Notable gainers included Guangshantang and Rejing Bio, both reaching a 20% limit up, while other significant increases were seen in Jingxin Pharmaceutical, Haizheng Pharmaceutical, and Saily Medical, with respective rises of 10.02%, 10.02%, and 18.79% [1][2] - The sector experienced a net outflow of 296 million yuan in principal funds, with 93 stocks receiving net inflows, and five stocks exceeding 100 million yuan in net inflows, led by Zhongyuan Qihua with 183 million yuan [2][3] Group 2 - The top stocks by net inflow ratio included Saily Medical, Aosaikang, and Zhongyuan Qihua, with net inflow rates of 30.63%, 29.89%, and 20.01% respectively [3] - The innovative drug sector's top performers in terms of net inflow included Zhongyuan Qihua, Guangshantang, and Aosaikang, with net inflows of 182.94 million yuan, 156.95 million yuan, and 137.87 million yuan respectively [3][4] - The overall trading activity in the innovative drug sector showed a mix of significant gains and losses, with some stocks like Anlikang and Zhenbaodao experiencing declines of 7.81% and 3.95% respectively [1][2][3]

Group 1 - The innovative drug sector is experiencing a strong opening, with Selin Medical (603716) achieving a four-day consecutive rise [1] - Tainkang (301263) and Zhongyuan Qihua (600645) opened high with a 6% increase [1] - Other companies such as Guangshengtang (300436), Weiming Pharmaceutical (002581), and Changchun High-tech (000661) also saw significant opening gains [1] Group 2 - Dark pool funds are flowing into these stocks, indicating increased investor interest [2]